Sökning: id:"swepub:oai:hhs.se:1155007050006056" >
Pharmaceutical pric...
Pharmaceutical pricing in a regulated market
-
- Ekelund, Mats (författare)
- Stockholm School of Economics,Handelshögskolan i Stockholm
-
- Persson, Björn (författare)
- Stockholm School of Economics,Handelshögskolan i Stockholm
-
(creator_code:org_t)
- Massachusetts Institute of Technology Press (MIT Press): Economics Titles, 2003
- 2003
- Engelska.
-
Ingår i: Review of Economics and Statistics. - : Massachusetts Institute of Technology Press (MIT Press): Economics Titles. - 1530-9142 .- 0034-6535. ; 85:2, s. 298-306
- Relaterad länk:
-
https://research.hhs...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- We compare how new pharmaceuticals are priced in the price-regulated Swedish market with how they are priced in the U.S. market, as studied by Lu and Comanor (1998). We collect a data set consisting of all new chemical entities (NCEs) launched in Sweden between 1987 and 1997, and test the same models as Lu and Comanor. In line with their results, we find that introductory prices depend on the degree of therapeutic innovation. Contrary to the results from the U.S. market, Swedish real prices for NCEs fall substantially over time for all classes of therapeutic innovation. Also contrary to the findings of Lu and Comanor, we find no effect of the presence of branded substitutes on either introduction prices or price dynamics. Our results indicate that the price regulation discourages price competition between brandname drugs.
Ämnesord
- SAMHÄLLSVETENSKAP -- Ekonomi och näringsliv -- Nationalekonomi (hsv//swe)
- SOCIAL SCIENCES -- Economics and Business -- Economics (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas